Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

Ian W. Flinn, MD PhD, Jonathon B. Cohen, MD MS, Luke P. Akard, MD, Samantha Jaglowski, MD MPH, Michael Vasconcelles, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Greg Motz, PhD, Veronika Bachanova, MD PhD

Blood (2018) 132 (Supplement 1): 2966.

https://doi.org/10.1182/blood-2018-99-111622

Published: 2018

Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD

Blood (2018) 132 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2018-99-111729

Published: 2018

Journal Articles

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Luke Paul Akard, MD, Samantha Jaglowski, MD, Steven M. Devine, MD, Matthew S. McKinney, MD, Michael Vasconcelles, MD, Heather Huet, PhD, Seth Ettenberg, PhD, Ann Ranger, PhD, Jeremy S. Abramson, MD MMSc

Blood (2017)

https://doi.org/10.1182/blood.V130.Suppl_1.580.580

Published: 2017

Journal Articles

Targeting CD20+ Relapsed Refractory B Cell Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR) Engineered Autologous T Cells, in Combination with Rituximab

Heather A Huet, PhD, Casey Judge, M.S., R. Anthony Barnitz, PhD, Ryan Boomer, BSc, Kathleen McGinness, PhD, John Shin, BSc, Tooba Cheema, PhD, Kathleen Whiteman, M.S., Birgit Schultes, PhD, Ann Ranger, PhD, Lan Cao, PhD, Geoffrey Hodge, PhD, Michael J. Vasconcelles, MD, Seth A Ettenberg, PhD

Blood (2016) 128 (22): 3512.

https://doi.org/10.1182/blood.V128.22.3512.3512

Published: 2016

Journal Articles

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

Mathangi Srinivasan, Ryan Flynn, Andrew Price, Ann Ranger, Jeffrey L. Browning, Patricia A. Taylor, Jerome Ritz, Joseph H. Antin, William J. Murphy, Leo Luznik, Mark J. Shlomchik, Angela Panoskaltsis-Mortari, Bruce R. Blazar

Blood (2012) 119 (6): 1570–1580.

https://doi.org/10.1182/blood-2011-07-364414

Published: 2012

Includes: Supplemental data

Journal Articles

Donor B-Cell Alloantibody Deposition and Germinal Center Formation Are Required for the Development of Murine Chronic Gvhd and Bronchiolitis Obliterans

Mathangi Srinivasan, PhD, Ryan Flynn, Andrew Price, Ann Ranger, PhD, Jeffrey L Browning, Patricia A Taylor, DVM, Jerome Ritz, MD, Joseph H. Antin, MD, William J Murphy, PhD, Leo Luznik, Mark Shlomchik, MD, PhD, Angela Panoskaltsis-Mortari, PhD, Bruce R. Blazar, MD

Blood (2011) 118 (21): 307.

https://doi.org/10.1182/blood.V118.21.307.307

Published: 2011

NARROW

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Targeting CD20+ Relapsed Refractory B Cell Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR) Engineered Autologous T Cells, in Combination with Rituximab

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

Donor B-Cell Alloantibody Deposition and Germinal Center Formation Are Required for the Development of Murine Chronic Gvhd and Bronchiolitis Obliterans

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only